Prevalence of comorbidities in myeloablative and reduced-intensity conditioning cohorts from the CIBMTR and EBMT. The CIBMTR cohort consists of 3685 patients, median age 57.5 (IQR, 50.5, 63.9); the EBMT cohort consists of 9323 patients with a median age of 51.5 years (42.8, 62.1). Both cohorts were selected to include only patients with AML in complete remission. CVA, cerebrovascular accident; IBD, inflammatory bowel disease; IQR, interquartile range; PUD, peptic ulcer disease; pulm, pulmonary disease; sCr, serum creatinine. Data adapted from Fein et al.³  and Farhadfar et al.⁴⁶